Skip to main content
Premium Trial:

Request an Annual Quote

Eisai, Sysmex to Develop Dx, CDx for Dementia

NEW YORK (GenomeWeb) – Eisai and Sysmex said yesterday that they have entered into a comprehensive non-exclusive collaboration agreement to create new diagnostics for dementia.

Under the agreement, Sysmex will contribute its expertise and know-how in clinical diagnostics, as well as technologies for the highly sensitive detection of genetic, protein, and cellular biomarkers in blood samples. For instance, the company can offer BEAMing digital PCR and highly automated flow cytometry technology, both of which it brought on board with its 2013 acquisitions of Inostics and Partec.

Eisai, meantime, will contribute its experience and knowledge in drug discovery for dementia, and product-related information for Aricept, its treatment for Alzheimer's disease and dementia with Lewy bodies.

Together the companies said they aim to discover next-generation tests that will enable early diagnosis and treatment selection and monitoring. Sysmex will lead diagnostic development, and will exclusively market the diagnostics worldwide after receiving regulatory approval. Eisai will receive payments for meeting development milestones and launching products, and will receive royalties on sales. It will also use the diagnostics for drug discovery and development in the area of dementia.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.